

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	3351663
<b>Application Number:</b>	10078949
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	8454
<b>Title of Invention:</b>	OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA
<b>First Named Inventor/Applicant Name:</b>	Stanley T. Crooke
<b>Customer Number:</b>	32650
<b>Filer:</b>	Jane E. Inglese/Heather Kite
<b>Filer Authorized By:</b>	Jane E. Inglese
<b>Attorney Docket Number:</b>	ISIS-5027
<b>Receipt Date:</b>	23-MAY-2008
<b>Filing Date:</b>	20-FEB-2002
<b>Time Stamp:</b>	15:04:42
<b>Application Type:</b>	Utility under 35 USC 111(a)

### Payment information:

Submitted with Payment	no
------------------------	----

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes) /Message Digest	Multi Part /.zip	Pages (if appl.)
1	Information Disclosure Statement Letter	ISIS-5027_SIDS_5-23-08.PDF	205859 9f5be46156f0aabb95a047225fz9a4d597851353	no	26

**Warnings:**

**Information:**

2	Information Disclosure Statement (IDS) Filed	ISIS-5027_1449.PDF	155633 4f6dc33699ccca223ab4e19113955d7c b0e0ee	no	3
<b>Warnings:</b>					
<b>Information:</b>					
This is not an USPTO supplied IDS fillable form					
3	Foreign Reference	EP266168.pdf	541179 f9f4f093a07759f4d7c3de4b0547d5c7 cad777db	no	12
<b>Warnings:</b>					
<b>Information:</b>					
4	Foreign Reference	WO1994002498A1.pdf	1398746 f96d276667875e2c3130fb31c085dd00 25d57917	no	37
<b>Warnings:</b>					
<b>Information:</b>					
5	Foreign Reference	WO1996007392.pdf	2224316 53d1181d4e939c253c058ab2ca5f5d0c 13ab7027	no	70
<b>Warnings:</b>					
<b>Information:</b>					
6	Foreign Reference	WO2002044321.pdf	4300156 406e33ee0c1b2479e114520902a7b983 2af95155	no	97
<b>Warnings:</b>					
<b>Information:</b>					
7	NPL Documents	Alahari_JPharmExpTher_19 98_419-428.pdf	414972 51a2c656e082c70ee2161534b96c7da5 47193543	no	10
<b>Warnings:</b>					
<b>Information:</b>					
8	NPL Documents	Beigelman_JBiolChem_1995 _25702-25708.PDF	684865 cad0872ed0dd4c90241f56chl42ee0c2e a54e050b	no	7
<b>Warnings:</b>					
<b>Information:</b>					
9	NPL Documents	Berger_NuclAcidsRes_1998 _2473-2480.PDF	1176603 ddbf173a4429411895650036509ed1900 261c9d4	no	8
<b>Warnings:</b>					
<b>Information:</b>					
10	NPL Documents	Bevilacqua_BioChem_1996 9983-9994.pdf	396526 b1eb683f15c485196dc059ca0ca3f002 031561c	no	12

<b>Warnings:</b>					
<b>Information:</b>					
11	NPL Documents	Boutla_CurrBiol_2001_1776-1780.pdf	207849 94094B644545ce110a4ce58-4a9f32be 8955485	no	5
<b>Warnings:</b>					
<b>Information:</b>					
12	NPL Documents	Cook_AntiCancerDrugDes_585-607.pdf	3339117 48b4040b485d5d9ae17ca3f3c55563a3b 4dc5ef3b	no	23
<b>Warnings:</b>					
<b>Information:</b>					
13	NPL Documents	Damha_JAmChem_12976-12977.pdf	374132 7b6d8429aa551f0148c8c048c5d1d25 b71b021	no	2
<b>Warnings:</b>					
<b>Information:</b>					
14	NPL Documents	Elbashir_EMBOJ_2001_6877-6888.pdf	2125165 58c6d119f11dc274e0f61a02b0a753acdb0 a076326	no	12
<b>Warnings:</b>					
<b>Information:</b>					
15	NPL Documents	hammond_Nature_2001_110-119.pdf	1068268 c94a8ccab3739a3b4bc85c4399ae157 0a3d1c90	no	10
<b>Warnings:</b>					
<b>Information:</b>					
16	NPL Documents	Kimura-Harada_FEBSLett_335-338.pdf	260191 e7237ac49b0f27b165c11257da437db6 6553b60	no	4
<b>Warnings:</b>					
<b>Information:</b>					
17	NPL Documents	Koizumi_NuclAcidsRes_1989_7059-7071.PDF	432548 97b3383e92c9a2b69143421a145c9d8 5e96a323b	no	13
<b>Warnings:</b>					
<b>Information:</b>					
18	NPL Documents	Kuimelis_NuclAcidsRes_1994_1429-1436.PDF	615073 83a732660f1180189898020a08099b05 06c370b	no	8
<b>Warnings:</b>					
<b>Information:</b>					
19	NPL Documents	Lesnik_Biochem_1995_10807-10815.pdf	870577 27e3eeea4a5ae1fb4ba6396c4a297e1b cd59a3a5	no	9

<b>Warnings:</b>					
<b>Information:</b>					
20	NPL Documents	Parrish_Molecular_Cell_2000_1077_1087.PDF	852241 2ba500e934d03778a237c6516720aa d39b78	no	11
<b>Warnings:</b>					
<b>Information:</b>					
21	NPL Documents	Porta_Biotechnol_161-164.PDF	416967 9c115db0c0c6b2f9c15a7c986c1201ca 6529371	no	4
<b>Warnings:</b>					
<b>Information:</b>					
22	NPL Documents	Shuman_JBiolChem_1993_18943-18950.PDF	1057587 064554f5c2f907c571c151c6123acbbba 729919	no	8
<b>Warnings:</b>					
<b>Information:</b>					
23	NPL Documents	Tosquellas_2069-2074.pdf	748954 982a26c17f0db0381ed6d13345a54ec 0e343941	no	6
<b>Warnings:</b>					
<b>Information:</b>					
24	NPL Documents	Tracewell_ToxicolApplPharmacol_179-184.pdf	533926 40317e01f0eececb5d5dc45ac78f24480e b7549b7	no	6
<b>Warnings:</b>					
<b>Information:</b>					
25	NPL Documents	Tuschl_MolIntervent_158-167.pdf	585527 ab6b691ca25e9f5ad0c0c682f9546ad0 0e453967	no	10
<b>Warnings:</b>					
<b>Information:</b>					
26	NPL Documents	Veronese_NuclAcidsRes_3625-3635.pdf	1854952 3497ac5194b5e4e005b54a2589ac139 8b2a82ac9	no	20
<b>Warnings:</b>					
<b>Information:</b>					
27	NPL Documents	Wilks_NuclAcidsRes_3625-3635.pdf	993593 0119a4ec26bc096d3d9f99599e0e43a0 a778a2648	no	11
<b>Warnings:</b>					
<b>Information:</b>					
28	NPL Documents	Wu_JBiolChem_2532-2542.pdf	1469078 51ba58647b9011e0a0f5c52a09e714da 50a91d7	no	11

<b>Warnings:</b>					
<b>Information:</b>					
29	NPL Documents	Yu_RNA_324-331.pdf	5741301 b39993e779d231e7eb68f15ef157920d6ef b432941	no	8
<b>Warnings:</b>					
<b>Information:</b>					
30	NPL Documents	Yu_BioorgMedChem_1685-1 692.pdf	686717 648975d47a2a88f161a212384a2529d2a 24ef3b0c	no	7
<b>Warnings:</b>					
<b>Information:</b>					
31	NPL Documents	Table_rej.PDF	137196 838ce7cd5784a5793d88425c18a39522a3 e9926917	no	24
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>			35869814		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><b><u>New Applications Under 35 U.S.C. 111</u></b>          If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><b><u>National Stage of an International Application under 35 U.S.C. 371</u></b>          If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><b><u>New International Application Filed with the USPTO as a Receiving Office</u></b>          If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					